Familial Mediterranean Fever (FMF) and Pregnancy: Literature Review
https://doi.org/10.25557/2073-7998.2020.11.4-12
Abstract
The review summarizes current information on the impact of FMF and its treatment on pregnancy outcomes, and analyses the hypothetical teratogenicity of colchicine. In the case of colchicine resistance/intolerability, the possibility of using other drugs during pregnancy, including genetically engineered biological drugs, among which interleukin 1 inhibitors are preferred for FMF. An evolutionary view is presented on the need for amniocentesis in FMF patients receiving colchicine during conception and pregnancy, as well as in cases where colchicine therapy was performed to husbands during conception with their wives. Emphasis is placed on the safety aspects of therapy, the main provisions of which are presented in the clinical recommendations for the treatment of FMF of the European Anti-Rheumatic League (EULAR, 2016). According to these recommendations, colchicine should not be discontinued during conception, pregnancy or lactation; today’s evidence does not support amniocentesis.
About the Author
P. O. Sotskiy
Center of Medical Genetics and Primary Health Care
Russian Federation
Russian Federation
References
1. Ben-Chetrit E., Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003; 62:916-919.
2. Mijatovic V., Hompes P.G., Wouters M.G. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;108(2):171-176. doi: 10.1016/s0301-2115(02)00417-7
3. Rabinovitch O., Zemer D., Kukia E. et al. Colchicine treatment in conception and pregnancy: two hundred thirty one pregnancies in patients with Familial Mediterranean Fever. Am J Reprod Immunol. 1992; 28:245-246.
4. Ehrenfeld M., Brzezinski A., Levy M., Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol. 1987; 94(12):1186-1191. doi:10.1111/j.1471-0528.1987.tb02320.x
5. Zemer D., Pras M., Shemer Y. et al. Daily prophylactic colchicine in familial Mediterranean fever. In: Amyloid and amyloidosis. Proc 3rd International Symposium on Amyloidosis. Amsterdam-Oxford-Prinston: Exerpta Medica. 1980:580-583.
6. Michael O., Goldman R.D., Koren G. Safety of colchicine therapy during pregnancy. Can Fam Physician. 2003; 49:967-969.
7. Ben-Chetrit E., Levy M. Colchicine:1998 update. Semin Arthritis Rheum.1998;28(1):48-59. doi:10.1016/s0049-0172(98)80028-0
8. Amoura Z., Schermann J.M., Wechsler B. et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol. 1994; 21(2):383.
9. Shoji R., Makino S. Preliminary notes on the teratogenic and embryocidal effects of colchicine on mouse embryos. Proc Jpn Acad. 1966; 42:822-827.
10. Berkenstadt M., Weisz B., Cuckle H. et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193:1513-6. doi:10.1016/j.ajog.2005.03.043.
11. Ditkoff E.C., Sauer M.V. Successful pregnancy in a familial Mediterranean fever patient following assisted reproduction. J Assist Reprod Genet. 1996;13(8):684-685. doi:10.1007/BF02069651.
12. Ben-Chetrit E., Ben-Chetrit A., Berkun Y., Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res. 2010; 62:(2):143-148. doi:10.1002/acr.20061.
13. Tutuncu L., Atasoyu E.M., Evrenkaya R., Mungen E. Familial mediterranean fever-related nephrotic syndrome and successful full-term pregnancy. Arch Med Res. 2006; 37(1):178-180. doi: 10.1016/j.arcmed.2005.04.013.
14. Akar Y., Yucel I., Akar M.E. et al. Long-term fluctuation of retinal sensitivity during pregnancy. Can J Ophthalmol. 2005; 40(4):487-491. doi:10.1016/S0008-4182(05)80011-0
15. Indraratna P., Virk S., Gurram D., Day R. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology. (Oxford) 2018; 57(2):382-387. doi:10.1093/rheumatology/ kex353
16. Dotters-Katz S., Kuller J., Price T. The impact of familial Mediterranean fever on women’s health. Obstet Gynecol Surv. 2012; 67(6):357-64. doi:10.1097/OGX.0b013e318259ed3a
17. Yanmaz M.N., Özcan A.J., Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol. 2014; 33(10):1385-1388. doi:10.1007/s10067-014-2709-9
18. Sarı İ., Birlik M., Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1(1):21-33. doi:10.5152/eurjrheum.2014.006
19. Ozdogan H., Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019;48(1):61-76. doi:10.1016/j.lpm.2018.08.014.
20. Update of the Joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplant Association (EULAR/ER-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924
21. Yasar O., Iskender C., Kaymak O. et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med. 2014;27(7):733-736. doi:10.3109/14767058.2013.837446
22. Nabil H., Zayed A., State O., Badawy A. Pregnancy outcome in women with familial Mediterranean fever. J Obstet Gynaecol. 2012;32(8):756-759. doi:10.3109/01443615.2012. 698667
23. Fortunato S.J., Menon R., Lombardi S.J. Support for an infectioninduced apoptotic pathway in human fetal membranes. Am J Obstet Gynecol. 2001;184:1392-1397. doi:10.1067/mob.2001.115434
24. Romero R., Friel L.A., Velez Edwards D.R., et al. A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Am J Obstet Gynecol. 2010;203:361. doi:https://doi.org/10.1016/j.ajog.2010.05.026
25. Ofir D., Levy A., Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2008; 141:115-118. doi:10.1016/j.ejogrb.2008.07.025
26. Shepard T.H. Catalog of teratogenic agents, 6th ed. Baltimore, MD: Johns Hopkins University Press; 1989:164-166.
27. Ferreira N.R., Buoniconti A. Trisomy after colchicine therapy. Lancet. 1968;2:1304.
28. Ben-Chetrit E., Berkun Y., Ben-Chetrit E., Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34(2):549-552. doi: 10.1016/j.semarthrit.2004.07.004
29. Wang X., Chen C., Wang L. et al. Conception, early pregnancy loss, and time to clinical pregnancy: a populationbased prospective study. Fertil Steril 2003;79:577-584. doi: 10.1016/s0015-0282(02)04694-0
30. Ben-Chetrit E., Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991; 20:241-246. doi:10.1016/0049-0172(91)90019-v
31. Cestari A.N., Botelho Vieira Filho J.P., Yonenaga Y. et al. A case of human reproductive abnormalities possibly induced by colchicine treatment. Rev Bras Biol. 1965;25:253.
32. Cohen M.M., Levy M., Eliakim M.A. Cytogenic evaluation of long-term colchicine therapy in the treatment of Familial Mediterranean fever (FMF). Am J Med Sci. 1977;274(2):147-152. doi:10.1097/ 00000441-197709000-00005
33. Diav-Citrin O., Shechtman S., Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203:144. doi:10.1016/j.ajog.2010.02.063
34. Ben-Chetrit E., Scherrmann J.M., Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39:1213-1217. doi:10.1002/art.1780390721
35. Milunsky J.M. Breast-feeding during colchicine therapy for familial Mediterranean fever. J Pediatr. 1991;119:164. doi:10.1016/s0022-3476(05)81070-4
36. Mordel N., Birkenfeld A., Rubinger D. et al. Successful full-term pregnancy in familial Mediterranean fever complicated with amyloidosis: case report and review of the literature. Fetal Diagn Ther. 1993;8:129-134. doi:10.1159/000263761
37. Shimoni Y., Shalev E. Pregnancy and complicated familial Mediterranean fever. Int J Gynaecol Obstet. 1990;33(2):165-169. doi:10.1016/0020-7292(90)90591-8.
38. Yazicioğlu A., Turgal M., Senem O. et al. Pregnancy Outcome in Women with familial Mediterranean fever: A Retrospective Analysis of 50 Cases with a 10-Year Experience. Arch Rheumatol. 2014;29(2):94-98. doi: 10.5606/ArchRheumatol.2014.3707
39. Ozen S., Demirkaya E., Erer B. et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016;75:644-651. doi: 10.1136/annrheumdis- 2015-208690
40. İlgen U., Küçükşahin O. Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. Eur J Rheumatol 2017;4(1):66-67. doi:10.5152/ eurjrheum.2017.16075
41. Lidar M., Yonath H., Shechter N. et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12(1):72-76. doi:10.1016/j.autrev.2012.07. 025.
42. Sönmez H.E., Batu E.D., Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res 2016;9:13-20. doi:10.2147/JIR.S91352
43. Livneh A., Cabili S., Zemer D. et al. Effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. J. Rheumatol.1993;20:1519-1523.
44. Hentgen V., Grateau G., Kone-Paut I. et al. EULAR recommendations for the practical maganement of Familial Mediterranean Fever. Seminars in arthritis and rheumatism. Elsevier 2013;387-391. doi:10.1016/j.semarthrit.2013.04.011
45. Yilmaz N.K., Kara M., Kaba M. et al. Effect of Familial Mediterranean Fever on IVF outcome: A Retrospective Case Series. Acta Clin Croat 2016; 55:254-258. doi:10.20471/acc.2016.55.02.11.
46. Ozdogan H., Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev ClinImmunol. 2017;13(5):393-404. doi:10.1080/1744666X.2017.1313116
47. Heng Y.J., Liong S., Permezel M. et al. The interplay of interleukin-1 system in pregnancy and labor. Reprod Sci. 2011;21:122-130. doi:10.1177/1933719113492204
48. Berger C.T., Recher M., Steiner U., Hauser T.M. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68(11):1794-1795. doi:10.1136/ard.2008.105833.
49. Chang Z., Spong C.Y., Jesus A.A. et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014; 66:3227-3232. doi: 10.1002/ art.38811
50. Fischer-Betz R., Specker C., Schneider M. Successfull outcome of two pregnancies in patients with adult onset Still’s disease treated with IL-1 receptor antagonist (anakinra) Clin Exp Rheumatol. 2011; 29:1021-1023.
51. Lachman H.J., Ozdogan H., Simon A. et al. Anti IL-1 therapies and pregnancy outcome. Pediatr Rheumatol Online J. 11(Suppl 1):A269. doi:10.1186/1546-0096-11-S1-A269
52. Ozdogan H., Ugurlu S., Ergezen B. The pregnancy outcomes in patients who are exposed to IL-1 blockade with anakinra. Ann Rheum Dis. 2015;74:400-401.
53. Youngstein T., Hoffman P., Gul A. et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology. 2017;56:2102-2108. doi:10.1093/rheumatology/ kex305
Review
For citations:
Sotskiy P.O. Familial Mediterranean Fever (FMF) and Pregnancy: Literature Review. Medical Genetics. 2020;19(11):4-12. (In Russ.) https://doi.org/10.25557/2073-7998.2020.11.4-12
Views:
617
Email this article 